Protocol for the Examination of Specimens From Patients With Wilms and Other Pediatric Renal Tumors

Version: WilmsTumor 3.2.0.1  Protocol Posting Date: August 2016
Includes the Children's Oncology Group staging system

For accreditation purposes, this protocol should be used for the following procedures AND tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resection</td>
<td>Includes specimens labeled partial nephrectomy and radical nephrectomy</td>
</tr>
<tr>
<td>Tumor Type</td>
<td>Description</td>
</tr>
<tr>
<td>Wilms tumor</td>
<td></td>
</tr>
</tbody>
</table>

This protocol is NOT required for accreditation purposes for the following:

<table>
<thead>
<tr>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy</td>
</tr>
<tr>
<td>Primary resection specimen with no residual cancer (eg, following neoadjuvant therapy)</td>
</tr>
<tr>
<td>Additional excision performed after the definitive resection (eg, re-excision of surgical margins)</td>
</tr>
<tr>
<td>Cytologic specimens</td>
</tr>
<tr>
<td>Tumor Type</td>
</tr>
<tr>
<td>Pediatric renal tumors other than Wilms tumor</td>
</tr>
</tbody>
</table>

The following should NOT be reported using this protocol:

<table>
<thead>
<tr>
<th>Tumor Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal cell carcinoma (consider the Kidney protocol)</td>
</tr>
<tr>
<td>Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols)</td>
</tr>
</tbody>
</table>

Authors
Erin Rudzinski, MD*; Elizabeth Perlman, MD*; Grace Kim, MD; Neil Sebire

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.

* Denotes primary author. All other contributing authors are listed alphabetically.

Important Note
First priority should always be given to formalin-fixed tissues for morphologic evaluation. The second priority for tissue processing may include snap-freezing up to 1 g (minimum of 100 mg) of tumor for molecular studies (Note A).

For more information, contact: The Children’s Oncology Group Biopathology Center.
Phone: (614) 722-2890 or (800) 347-2486.
Accreditation Requirements
This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

- **Core data elements** are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is "not applicable" or "cannot be determined".
- **Conditional data elements** are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
- **Optional data elements** are identified with “+” and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution).

Synoptic Reporting
All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

- Data element: followed by its answer (response), outline format without the paired “Data element: Response” format is NOT considered synoptic.
- The data element must be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate.
- Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  - Anatomic site or specimen, laterality, and procedure
  - Pathologic Stage Classification (pTNM) elements
  - Negative margins, as long as all negative margins are specifically enumerated where applicable
- The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location. Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report i.e. all required elements must be in the synoptic portion of the report in the format defined above.

CAP Laboratory Accreditation Program Protocol Required Use Date: April 2017
Surgical Pathology Cancer Case Summary

Protocol posting date: August 2016

KIDNEY, PEDIATRIC RENAL TUMORS: Biopsy, Resection

Note: This case summary is recommended for reporting biopsy, but is not required for accreditation purposes.

Note: For bilateral tumors, complete a separate case summary for each kidney.

Select a single response unless otherwise indicated.

Procedure (Notes A and B)

Biopsy
___ Core biopsy
___ Incisional biopsy
___ Excisional biopsy

Resection
___ Partial nephrectomy
___ Radical nephrectomy
___ Other (specify): ____________________________
___ Not specified

Specimen Weight (applicable to resection specimens only) (Note B)
Nephrectomy weight: ____ g

Specimen Laterality (required for bilateral tumors only)
___ Right
___ Left
___ Not specified

Tumor Size
Greatest dimension: ___ cm
+ Additional dimensions: ___ x ___ cm
___ Cannot be determined (explain): ____________________________

For specimens with multiple tumors, specify greatest dimension of each additional tumor:
  Greatest dimension tumor #2: ___ cm
  Greatest dimension tumor #3: ___ cm
  Other (specify): ____________________________

Tumor Focality
___ Unifocal
___ Multifocal
___ Number of tumors in specimen (specify): ____________________________
___ Cannot be determined (explain): ____________________________

Tumor Extent (applicable to resection specimens only) (select all that apply) (Note C)

Gerota’s Fascia
___ Gerota’s fascia intact

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
___ Gerota’s fascia disrupted
___ Cannot be determined

**Renal Sinus**
___ No renal sinus involvement by tumor identified
___ Tumor minimally extends into renal sinus soft tissue
___ Tumor more than minimally involves renal sinus soft tissue
___ Tumor involves lymph-vascular spaces in the renal sinus
___ Cannot be determined (explain): __________________________

**Renal Vein**
___ Renal vein invasion present
___ No renal vein invasion identified
___ Cannot be determined

**Renal Capsule**
___ Extension beyond renal capsule present
___ No extension beyond renal capsule
___ Cannot be determined (explain): __________________________

**Adjacent Organ Involvement**
___ Tumor extension into adjacent organ present (specify organ: ________________)
___ No tumor extension into adjacent organs identified
___ Cannot be determined

**Margins**
___ Cannot be assessed
___ Uninvolved by tumor
    + Distance of tumor from closest margin(s): ____ cm
    + Specify margin: __________________________
___ Involved by tumor
    Specify: __________________________

**Histologic Type (Note D)**
___ Wilms tumor, favorable histology
___ Wilms tumor, focal anaplasia
___ Wilms tumor, diffuse anaplasia
___ Nephrogenic rest only
___ Congenital mesoblastic nephroma (cellular, classic, or mixed)
___ Clear cell sarcoma
___ Rhabdoid tumor
___ Other (specify): __________________________
___ Malignant neoplasm, type cannot be determined (explain): __________________________

**+ Nephrogenic Rests (select all that apply) (Note E)**

+ ___ No nephrogenic rests identified
+ ___ Nephrogenic rests present
    + ___ Intralobar
    + ___ Perilobar
        + ___ Diffuse, hyperplastic
        + ___ Multifocal
        + ___ Focal
    + ___ Nephrogenic rests, unclassified
+ ___ Cannot be determined

*Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.*
Posttherapy Histologic Classification (select all that apply)

The histologic evidence of response to therapy may be used to guide further therapy. Therefore tumors that have previously undergone therapy should be given a posttherapy classification (described in detail in Note D).

+ ___ No known preoperative therapy (not applicable)
+ ___ Low risk (no viable Wilms tumor present other than scattered nephroblastic tubules that may represent residual nephrogenic rest)
+ ___ Intermediate risk
  + ___ Viable tumor present comprising <33% of mass, regardless of histology
  + ___ Viable tumor present comprising >33% of mass, with blastemal histology present in <66% of viable tumor
+ ___ High risk (viable tumor >33% of mass with blastemal histology present in >66% of viable tumor)
+ ___ Cannot be determined

Regional Lymph Nodes
___ No nodes submitted or found

Number of Lymph Nodes Examined
Specify: ____
___ Number cannot be determined (explain): ______________________

Number of Lymph Nodes Involved
Specify: ____
___ Specify site(s) if known: ________________________________
___ Number cannot be determined (explain): ______________________

Distant Metastasis (required only if confirmed pathologically in this case)

Note: Distant metastasis category includes both hematogenous metastasis or lymph node metastasis outside the abdomen-pelvic region (beyond the renal drainage system).
___ Present
___ Specify site(s) if known: ________________________________

Children’s Oncology Group Staging System for Pediatric Renal Tumors Other Than Renal Cell Carcinoma (select all that apply) (Note F)

Note: Local stage must be assigned by the pathologist with the caveat that he or she may not be aware of clinical or radiographic information important in assigning the clinical or overall stage (ie. presence of metastatic disease).
___ Not applicable (nephrogenic rests only)
___ Local Stage I: Tumor limited to kidney and completely resected (requires all of the following to be true)
  + ___ No penetration of renal capsule by tumor identified
  + ___ No tumor involvement of extrarenal or renal sinus lymph-vascular spaces identified
  + ___ No tumor metastasis to lymph nodes identified
___ Local Stage II: Tumor extends beyond kidney for 1 or more of the below reasons but is completely resected, with negative surgical margins and negative regional lymph nodes
  + ___ Tumor extends through the renal capsule
  + ___ Tumor involvement of extrarenal or renal sinus lymph-vascular spaces present
  + ___ Tumor involves renal vein, but has not been transected and is not attached to vein wall at resection margin
  + ___ Tumor more than minimally involves the renal sinus soft tissue
___ Local Stage III: Residual tumor is suspected for 1 or more of the below reasons
  ___ Tumor present at margin(s) of resection
  ___ Tumor rupture identified
  ___ Tumor spill before or during surgery identified
  ___ Piecemeal excision of tumor (removal of tumor in more than 1 piece)
  ___ Metastatic tumor in regional lymph nodes identified
  ___ History of renal tumor biopsy before definitive surgery

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
___ Stage IV: Metastatic disease
  + ___ Hematogenous metastases or lymph node metastases outside the abdomino-pelvic region (beyond renal drainage system, eg, lung, liver)
___ Stage V: Bilateral renal involvement at diagnosis

  Note: Each side should be staged separately in separate case summaries, according to above criteria, as stage I through IV.

  Specify (both): Right kidney stage: ___
  Left kidney stage: ___

+ Additional Pathologic Findings (Notes G and H)
+ Specify: ______________________________

+ Comment(s)
Explanatory Notes

A. Frozen Section
Because of the high number of false-positives, intraoperative frozen sections should be avoided unless the operative procedure will be altered by the result. Biopsies of pediatric renal tumors present significant potential for diagnostic error, even on permanent section. However, frozen sections from the bivalved nephrectomy specimen—to ensure tumor viability or to prompt other differential diagnostic studies—may be of value.

For future potential molecular studies, viable tumor (1 g or more) should be snap-frozen (liquid nitrogen or cold isopentane) in 2 or more vials, along with a separate portion of nonneoplastic kidney (at least 1 vial). The latter serves as a useful control in molecular genetic studies and helps determine whether any detected genomic abnormalities are germline or intratumoral mutations. Nephrogenic rests may also be sampled and frozen for the same reasons.

B. Handling of Renal Specimens
With pediatric renal tumors, there are many issues that can interfere with making accurate diagnostic and staging decisions. The following guidelines are recommended to ensure that the necessary diagnostic features are preserved and properly examined:

- *Nephrectomy specimens should be submitted intact by the surgeon.* The surface of the specimen should be photographed and inked before bivalving to facilitate the recognition of displacement artifacts from the smearing of tumor cells over the specimen surface during sectioning, as well as to evaluate margins. Bivalving will cause the capsule in a fresh kidney to retract, possibly altering the relationship between the tumor and the capsule or surgical margin.

- The capsule from nephrectomy specimens must *never* be stripped. Invasion of the tumor into the capsule is a criterion in staging. In addition, nephrogenic rests are often subcapsular in location. The medial sinus margin is defined as the medial end of soft tissues surrounding the renal artery and vein.

- Inspect the renal vein for tumor thrombus because this is a common route by which Wilms tumor exits the kidney (Note D).

- The exact site from which each section or paraffin block is obtained may be documented by photograph, photocopy, or drawing. Often, this documentation is critical for recognizing staging problems and for the evaluation of focal versus diffuse anaplasia.

- Take at least 1 microscopic section per centimeter of maximal tumor diameter, with additional sampling of any suspicious lesions. The majority of random tumor sections should be taken from the periphery of the tumor, because this is where the invasive pattern of the tumor can be identified and its interface with the capsule and native kidney can be evaluated. Peripheral sections also demonstrate invasion of vessels within the intrarenal extension of the renal sinus. The renal sinus is that area in the hilum of the kidney occupied by the renal pelvis, as well as hilar vessels and fat. The renal cortex at the sinus lacks a capsule. The most important sections are those taken from regions of the sinus adjacent to the tumor to demonstrate involvement (or lack of involvement) of sinus vessels (Note D).

- For Wilms tumors that are multicentric, sample each nodule. More than 30% of Wilms nephrectomy specimens contain nephrogenic rests. Nephrogenic rests often appear paler than the typical nonneoplastic kidney parenchyma. These areas should be sampled. Nephrogenic rests have important implications concerning the risk of contralateral Wilms tumor development and may have other syndromatic implications. At least 1 random section of normal kidney and possibly more may be taken to detect nephrogenic rests microscopically (Note E).

- Nephrectomy weight may be an eligibility factor for some clinical trial protocols. Hence, this measurement is critical.
In addition to the capsular, vascular, and sinus sampling already described, routine sections taken for margins should include sampling of the distal ureter.

**C. Extent of Tumor**

**Evaluation of Renal Sinus Invasion**
The most common cause of upstaging upon central review is failure to appreciate renal sinus involvement. Renal sinus vascular involvement is easy to confirm when the tumor fills the lumen or invades the vascular wall. Displacement artifact is also readily identified when it is present in arterial lumina, when it is accompanied by abundant displacement artifact elsewhere, or when ink is present within the aggregates. More difficult are foci of unattached tumor intermingling with fibrin and red cells, or free-floating rounded tumor fragments that are not associated with other displacement artifact. The presence of these foci in children with small, otherwise stage I tumors not treated with adjuvant chemotherapy are biologically significant and should upstage the patient. The other difficulty with the evaluation of the renal sinus is the fact that it extends well into the kidney and is not limited to the hilum. The renal sinus can be identified by the presence of fat and mesenchymal tissue surrounding vascular structures. The involvement of soft tissue confined to the intrarenal portion of the renal sinus is considered to be limited (unless close to a surgical margin) and would not upstage a patient to stage II. However, the involvement of a vessel within the intrarenal portion of the renal sinus does upstage the patient to stage II. Intrarenal vascular invasion does not upstage a renal tumor.

**Evaluation of Renal Vein Invasion**
Caution should be used in the evaluation of the margin of the renal vein that contains a thrombus. The vein often retracts after the surgeon sections it, leaving a protruding tumor thrombus, which may erroneously be considered a positive margin. If the thrombus itself is not transected, and if the margin of the vascular wall itself does not contain tumor, this surgical margin is interpreted as being negative.

**D. Microscopic Examination**

**Favorable Histology Wilms Tumor**
Classic Wilms tumors present with a mixture of blastemic, stromal, and epithelial cell types. A common difficulty faced by pathologists interpreting a pediatric renal mass is the distinction between a hyperplastic perilobar nephrogenic rest and a Wilms tumor because these may be cytologically identical. The most helpful histologic feature is the absence of a peritumoral fibrous capsule in perilobar nephrogenic rests. Many other neoplasms may have a histologic appearance similar to blastemal-predominant Wilms tumors. The most common tumors misdiagnosed as Wilms tumors are undifferentiated neuroblastoma, primitive neuroectodermal tumor, and synovial sarcoma. The most helpful feature that favors the diagnosis of Wilms tumor is the presence of overlapping nuclei with finely dispersed chromatin. Similarly, epithelial-predominant Wilms tumors show considerable histologic overlap with papillary renal cell carcinoma and metanephric adenoma. A more detailed differential diagnosis of pediatric renal tumors is provided elsewhere.

**Anaplastic Wilms Tumor**
Once a tumor has been diagnosed as Wilms tumor, it is necessary to determine whether it is of favorable histology or if anaplasia is present. Although anaplasia is present in only 5% of all cases, it is the major prognostic indicator and will place a tumor in an unfavorable histologic category.

The presence of anaplasia is a significant prognostic factor in Wilms tumor and places the tumor in an unfavorable category. Although the mechanism for unfavorable prognosis is unclear, anaplasia may be a marker of chemotherapy resistance. A diagnosis of anaplasia requires both (1) gigantic polyplody nuclei with increased chromatin content and major diameters at least 3 times those of adjacent cells and (2) the presence of multipolar or otherwise recognizably polyplody mitotic figures. On a small biopsy, a single multipolar mitotic figure or an unequivocally gigantic tumor cell nucleus may be sufficient criteria for diagnosis. Severe nuclear unrest is defined as nuclear pleomorphism or atypia approaching the criteria of anaplasia. Anaplasia should not be assessed in cells exhibiting rhabdomyoblastic differentiation, as these cells may show nuclear enlargement, pleomorphism, and hyperchromasia akin to regenerating skeletal muscle.
Criteria for focal versus diffuse anaplasia have been defined topographically and are rigorous. This topographic definition of focal anaplasia makes it mandatory that pathologists carefully document the exact site from which every section is obtained (e.g., on a diagram, specimen photocopy, and/or photograph of the gross specimen).

**Focal Anaplasia**
Diagnosis of focal anaplasia is warranted if all of the following are true:
- No anaplasia should be present in tumor within renal vessels or outside the kidney.
- Anaplasia must be confined to 1 or a few sharply localized regions within the primary intrarenal tumor site.
- Each focus of anaplasia must be surrounded on all sides by nonanaplastic tissue. This may require mapping of the tumor during submission.
- The remaining nonanaplastic tumor must not show severe nuclear unrest.
(The same criteria apply to posttreatment nephrectomies. There is no evidence to suggest that either chemotherapy or radiation therapy result in anaplasia.)

**Diffuse Anaplasia**
Diagnosis of diffuse anaplasia is warranted if any of the following are true:
- Anaplasia is present in tumor in any extrarenal site, including vessels of the renal sinus, extracapsular infiltrates, or nodal or distant metastases. Also, anaplasia is present in intrarenal vascular involvement by tumor.
- Anaplasia is present in a random biopsy.
- Anaplasia is unequivocally identified, but the tumor fails any of the above criteria for focal anaplasia.

Posttherapy Classification of Wilms Tumor: The response of a Wilms tumor to prior therapy may help guide the subsequent therapeutic strategy. For this reason, the Children’s Oncology Group is using the overall categories utilized by International Society of Paediatric Oncology (SIOP) when categorizing posttherapy tumors. As outlined above, these categories are based on the proportion of the tumor that is viable and blastemal, and only apply to favourable histology Wilms tumor. It is acknowledged that such quantitative analysis is quite difficult to reproduce and is highly dependent on how representative of the entire tumor the sections submitted are. The overall concept is that tumor that remains highly undifferentiated and proliferative following therapy will require more aggressive therapy going forward. Pathologists should, as always, use their best judgment. Such categorization is likely to change in the future.

The staging for posttherapy nephrectomy specimens differs only in the interpretation of areas of necrosis outside the kidney. The presence of necrotic tumor or chemotherapy-induced change (in the absence of viable tumor) in the renal sinus and/or within the perirenal fat is not regarded as a reason for upstaging following chemotherapy, providing the tumor is completely excised and does not reach the resection margins. In contrast, the presence of necrotic tumour or chemotherapy-induced changes in a lymph node or at the resection margins is regarded as proof of previous tumour with potential microscopic residual disease, and therefore the tumour is assigned stage III.

**Congenital Mesoblastic Nephroma**
There is a growing appreciation that congenital mesoblastic nephroma (CMN), a tumor of infancy, represents 2 genetically distinct tumors: the “classic” CMN (24% of cases), which may correspond to a type of fibromatosis; and “cellular” CMN (66% of cases), which corresponds to infantile fibrosarcoma and often contains the characteristic t(12;15), resulting in a fusion product detectable by reverse transcriptase polymerase chain reaction. Absence of this translocation does not exclude the diagnosis of cellular congenital mesoblastic nephroma. Occasional cases (10%) are classified as “mixed” CMN, owing to the presence of both histologic types. Currently, there is no consensus regarding the pathways through which mixed CMN may arise.

Approximately 10% of CMNs recur. Virtually all CMNs that recur are of the cellular subtype. Recurrences occur very rapidly, often within the first month of diagnosis. Virtually all recurrences occur by 1 year of age. More than half are local recurrences; however, pulmonary metastases have been identified in 20% of patients who relapse. However, the primary determinant of outcome is the completeness of excision. Surgeons should be educated and encouraged to secure wide margins, particularly medial margins, when resecting renal tumors in infants. Nonetheless, one can rarely be sure that the medial margin is clear; therefore, all patients should be followed
closely. Monthly abdominal ultrasounds should be performed for 1 year, with the hope of catching recurrences early enough to surgically excise them. Adjuvant chemotherapy is required when there is gross residual tumor. Radiation has no demonstrable effect.

Clear Cell Sarcoma of the Kidney
Clear cell sarcoma of the kidney (CCSK) is capable of mimicking, or being mimicked by, every other major neoplastic entity in the pediatric kidney. A genetic or histochemical feature specific to CCSK has been elusive. Immunohistochemical stains other than vimentin are inconsistent, but these negative results can help rule out other neoplasia in the differential diagnosis.

The histologic spectrum and clinical outcome of patients with CCSK have recently been reported by the National Wilms Tumor Study Group. Nearly all patients with stage I CCSK survive. Conversely, patients with more advanced disease have a propensity for local recurrence and metastasis. Recurrences can occur from years to decades after initial presentation, sometimes demonstrating a bland histology that differs from the primary tumor. The metastatic pattern tends to be more widespread than that of Wilms tumor and includes bone, brain, and soft tissue. There is a high recurrence rate and death rate even when treated by combination chemotherapy, but survival can be greatly improved after treatment with doxorubicin, which underscores the importance of identifying this neoplasm to facilitate early administration of more effective chemotherapy regimens.

There are several variants of CCSK, among which the following are most important:

Classical Pattern
The classical pattern of CCSK presents an evenly dispersed network of fine, arborizing vessels accompanied by a variable amount of spindle-cell stroma, subdividing the tumor into nests or cords of regular size, usually about 8 to 12 cells in width. The tumor cells are of regular size, usually with stellate cytoplasm, which often surrounds clear vacuoles. The nuclei are notably regular in size, with finely dispersed chromatin and usually inconspicuous nucleoli. Mitotic activity may be sparse. Scattered preexistent tubules or glomeruli often are dispersed through the peripheral regions of the tumor. This pattern of growth, which isolates and separates individual nephronic units or collecting tubules, is an important clue that one is not dealing with a Wilms tumor. The latter almost always has a sharply defined, “pushing” border.

Hyalinizing Pattern
The hyalinizing pattern of CCSK often has an osteoid-like, nonbirefringent matrix that separates tumor cells, giving an appearance reminiscent of osteosarcoma. A similar change maybe seen in rhabdoid tumor of the kidney (RTK).

Epithelioid Pattern
The epithelioid pattern is the most deceptive of the patterns of CCSK, in which the tumor cells align themselves along vessels in a manner mimicking the tubules of Wilms tumor. Often these cells form filigree-like strands.

Rhabdoid Tumor of the Kidney
This distinctive renal neoplasm most commonly is encountered in infants younger than 1 year of age and is extremely uncommon in patients older than 5 years. It is extremely aggressive and is the most prognostically unfavorable neoplasm of the kidney in early life. Rhabdoid tumors continue to present significant diagnostic challenges, particularly when they do not show overt rhabdoid features. However, the growing appreciation that this tumor arises in sites other than the kidney and the central nervous system, and the increased appreciation of the wide histologic spectrum of rhabdoid tumors, have contributed to a marked increase in their correct diagnosis. Rhabdoid tumor of the kidney should not be confused with the true myogenic cells, which are often found in Wilms tumors.

The most distinctive features of rhabdoid tumor of the kidney (RTK) are rather large cells with large vesicular nuclei, a prominent single nucleolus, and the presence in at least some cells of globular eosinophilic cytoplasmic inclusions composed of whorled masses of intermediate filaments. Another distinctive feature is the extremely aggressive, invasive pattern of this lesion. RTK has a diverse immunohistochemical profile. Tumors may be positive for many supposedly incompatible epitopes for epithelial, myogenous, neural, and mesenchymal cell types. Epithelial membrane antigen (EMA) should be included in the routine panel applied to small blue cell
tumors, largely because of the typical focal strong positivity for EMA (as well as a multitude of other markers) that rhabdoid tumors demonstrate.

Rapid advances in our understanding of the genetic events leading to the development of rhabdoid tumors have been made recently. It now is clear that both renal and extrarenal rhabdoid tumors carry homozygous deletions and/or mutations of the hSNF5/INI1 gene located at 22q11.2. Furthermore, germline mutations have been identified in individuals with both renal and central nervous system rhabdoid tumors. The INI1 gene causes conformational changes in the nucleosome, thereby altering histone-DNA binding and facilitating transcription factor access. The INI1 deletion can be evaluated with immunohistochemistry using the BAF47 antibody. This antibody shows strong nuclear staining in virtually all cell types except rhabdoid tumor cells. Important exceptions are renal medullary carcinoma and epithelioid sarcoma, which also often show loss of INI1 protein.

E. Nephrogenic Rests
Nephrogenic rests are regions of persistent embryonal tissue in the renal parenchyma and can be found in 30% to 44% of kidneys removed for Wilms tumor, 4% of kidneys removed for dysplasia or urinary tract malformations, and 0.21% to 0.87% of kidneys in pediatric autopsy series (higher incidence in infants <3 months of age). The term nephroblastomatosis refers to multiple or diffusely distributed nephrogenic rests. The 2 fundamental categories of nephrogenic rests are based on the topography of the lesion. Perilobar nephrogenic rests (PLNRs) are located at the periphery of the lobule and are usually subcapsular. They are often multiple and can be diffuse (diffuse perilobar nephrogenic rests or DPLNs). Microscopically, perilobar rests are well demarcated, but not encapsulated. They are typically composed of blastema and tubules with little intervening stroma. Similarly, tumors arising in association with PLNR are more likely to be blastemal or epithelial predominant. PLNRs are associated with higher birthweights and overgrowth syndromes, including Beckwith-Wiedemann syndrome. PLNRs serve as a marker of loss of imprinting or loss of heterozygosity for IGF-2. Intralobar nephrogenic rests (ILNRs) are located deep within the lobule and are usually solitary. They have indistinct margins with respect to the normal kidney. ILNR contain blastemal, tubular, and prominent stromal elements interspersed among normal glomerular and tubular elements. ILNR are also more often associated with early-onset, stromal-predominant Wilms tumor or Wilms tumor showing divergent (teratomatous) differentiation. ILNRs are a morphologic indicator of WT1 mutation and are strongly associated with WAGR (Wilms tumor, aniridia, genitourinary anomalies, and mental retardation) and Denys-Drash syndromes. It is thought that ILNRs result from an error earlier in nephrogenesis as compared with PLNRs, explaining the typical ILNR location deep within the lobule.

The presence of nephrogenic rests has clinical implications for their association with genetic syndromes as well as the risk for development of contralateral Wilms tumor, particularly in patients whose tumors are diagnosed in the first year of life.

F. Staging
The American Joint Committee on Cancer (AJCC) and International Union Against Cancer (UICC) TNM staging systems currently do not apply to Wilms tumor. The Children’s Oncology Group staging system for Wilms tumors is recommended and shown below.

Stage I
- Tumor limited to kidney and completely resected
- Renal capsule intact
- Tumor not ruptured or biopsied before removal
- No residual tumor apparent beyond margins of resection
- Renal vein and renal sinus vessels contain no tumor (intrarenal vessel involvement may be present)
- No lymph node involvement or distant metastases

Stage II
- Tumor extends beyond kidney but is completely resected
- Regional extension of tumor (vascular invasion outside the renal parenchyma or within the renal sinus, extensive renal sinus soft tissue invasion, and/or capsular penetration with negative excision margin)
Stage III
- Nonhematogenous metastases confined to the abdomen (eg, tumor in regional lymph nodes), including tumor implants on or penetrating the peritoneum
- Gross or microscopic tumor remains postoperatively (tumor at margins of resection)
- Tumor spill before or during surgery not confined to flank
- Piecemeal excision of the tumor (removal in more than 1 piece)
- Operative tumor spill confined to flank (no peritoneal contamination)
- Tumor biopsy before surgery

Stage IV
- Hematogenous metastases or lymph node metastases outside the abdomino-pelvic region (beyond renal drainage system, eg, lung, liver)

Stage V
- Bilateral renal involvement at diagnosis (each side should also be staged separately, according to above criteria, as I through IV)

G. Special Studies
The diagnosis of primary renal tumors in children remains largely based on examination of hematoxylin-eosin (H&E)-stained sections. Although some studies suggest that p53 immunostaining may be a more sensitive predictor of poor outcome than histologic assessment of anaplasia, such studies are fraught with difficulties in interpreting the outside limits of “positivity” as well as with interinstitutional variability in immunostaining techniques. Furthermore, some p53 mutations by their nature do not result in abnormal protein accumulation. However, strong, unequivocal abnormal p53 protein accumulation identified in a tumor that is suspicious for anaplasia may contribute to the diagnosis.

Other immunohistochemical stains are often utilized in the diagnosis of Wilms tumor, although it should always be remembered that no single or panel of markers can with 100% confidence either prove or exclude the diagnosis of Wilms tumor. WT1 is commonly positive in blastemal and epithelial elements but may be negative in up to 20% of Wilms tumors. CD56 is a sensitive marker of Wilms tumor but is quite nonspecific. Almost any other immunohistochemical marker may be found in Wilms tumors in the correct pathologic context.

No single cytogenetic or molecular abnormality has been consistently abnormal in Wilms tumor or its host, but constitutional deletions of the WT-1 tumor suppressor gene at 11p13 often predispose the patient to development of Wilms tumors. WAGR syndrome and Denys-Drash syndrome are characterized by the deletion or mutation of this gene. ILNRs are associated with WAGR and Denys-Drash syndromes. PLNRs are associated with Beckwith-Wiedemann syndrome, Perlman syndrome, and hemihypertrophy.

Genetic tests are often quite useful in the evaluation of several pediatric tumors arising in the kidney that mimic Wilms tumor. These include the characteristic translocation of cellular mesoblastic nephroma, t(12;15); and peripheral primitive neuroectodermal tumor, t(11;22). Molecular evaluation of the INI1 gene may be useful not only in the diagnosis of rhabdoid tumor, but also in counseling the family in the frequent event that this is constitutional.

Molecular tests such as loss of heterozygosity (LOH) at chromosomes 1p and 16q have been and remain active study questions for augmenting risk stratification and treatment for patients with Wilms tumor. However, the results of therapeutic interventions based on these findings are still pending and as such this testing should be considered a research question until mature data is available for publication.

H. Syndromes Associated With Wilms Tumor
The following syndromes are associated with Wilms tumor:
- Beckwith-Wiedemann syndrome
- Perlman familial nephroblastomatosis syndrome
- Denys-Drash syndrome
- Trisomy 18
- Neurofibromatosis
- Bloom syndrome
- WAGR syndrome

References